Log in

NASDAQ:INCY - Incyte Stock Price, Forecast & News

$80.50
-0.12 (-0.15 %)
(As of 01/20/2020 01:34 AM ET)
Today's Range
$80.05
Now: $80.50
$81.11
50-Day Range
$76.47
MA: $87.62
$95.68
52-Week Range
$72.00
Now: $80.50
$96.79
Volume1.37 million shs
Average Volume1.74 million shs
Market Capitalization$17.34 billion
P/E Ratio43.28
Dividend YieldN/A
Beta0.97
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.88 billion
Cash Flow$1.09 per share
Book Value$9.05 per share

Profitability

Net Income$109.49 million

Miscellaneous

Employees1,367
Market Cap$17.34 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.


Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.27. The biopharmaceutical company earned $551.58 million during the quarter, compared to analyst estimates of $534.73 million. Incyte had a net margin of 19.21% and a return on equity of 20.07%. Incyte's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period last year, the firm posted $0.41 EPS. View Incyte's Earnings History.

When is Incyte's next earnings date?

Incyte is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Incyte.

What price target have analysts set for INCY?

23 Wall Street analysts have issued 12-month price objectives for Incyte's shares. Their forecasts range from $65.00 to $121.00. On average, they expect Incyte's share price to reach $92.36 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Incyte.

What is the consensus analysts' recommendation for Incyte?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.

Has Incyte been receiving favorable news coverage?

Media stories about INCY stock have been trending positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Incyte.

Are investors shorting Incyte?

Incyte saw a drop in short interest in December. As of December 31st, there was short interest totalling 3,950,000 shares, a drop of 14.5% from the December 15th total of 4,620,000 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is presently 3.0 days. Approximately 1.9% of the shares of the stock are sold short. View Incyte's Current Options Chain.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Manning & Napier Group LLC (0.23%), Country Trust Bank (0.18%), Assenagon Asset Management S.A. (0.06%), Rhenman & Partners Asset Management AB (0.03%), Commerzbank Aktiengesellschaft FI (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Incyte stock include Barry P Flannelly, David W Gryska, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View Institutional Ownership Trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, First Hawaiian Bank, State of Alaska Department of Revenue, Tributary Capital Management LLC, Steward Partners Investment Advisory LLC, IFM Investors Pty Ltd and Raymond James Trust N.A.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View Insider Buying and Selling for Incyte.

Which major investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Rhenman & Partners Asset Management AB, Commerzbank Aktiengesellschaft FI, Country Trust Bank, Nisa Investment Advisors LLC, SevenBridge Financial Group LLC, Alpine Global Management LLC and Diversified Trust Co. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $80.50.

How big of a company is Incyte?

Incyte has a market capitalization of $17.34 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.

What is Incyte's official website?

The official website for Incyte is http://www.incyte.com/.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


MarketBeat Community Rating for Incyte (NASDAQ INCY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,087 (Vote Outperform)
Underperform Votes:  638 (Vote Underperform)
Total Votes:  1,725
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel